CCR6 and neoplasm: This study highlights hypoxia-induced tumor immunosuppression by TREM-1+ TAMs that attracts CCR6 + Foxp3 + Tregs, and TREM-1+ TAMs confers HCC resistance to Programmed cell death 1 ligand 1 (PD-L1) treatment.